A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00880217 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine 80 mg/d
DRUG: Placebo
DRUG: OROS methylphenidate HCl 54 mg/d
DRUG: JNJ-31001074 3 mg/d
DRUG: JNJ-31001074 1 mg/d
DRUG: JNJ-31001074 10 mg/d

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.